• OPEN AN ACCOUNT
Indian Indices
Nifty
24,334.20 -1.75
(-0.01%)
Sensex
80,242.24 -46.14
( -0.06%)
Bank Nifty
55,087.15 -304.10
( -0.55%)
Nifty IT
35,794.95 -125.45
( -0.35%)
Global Indices
Nasdaq
40,538.66 290.07
(0.72%)
Dow Jones
5,579.50 29.75
(0.54%)
Hang Seng
36,006.39 166.40
(0.46%)
Nikkei 225
8,463.46 46.12
(0.55%)
Forex
USD-INR
85.20 -0.17
(-0.20%)
EUR-INR
96.93 -0.07
(-0.07%)
GBP-INR
113.83 0.22
(0.19%)
JPY-INR
0.60 0.00
(0.27%)

EQUITY - MARKET SCREENER

Forbes & Company Ltd
Industry :  Construction
BSE Code
ISIN Demat
Book Value()
502865
INE518A01013
111.2170543
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
FORBESGOK
16.44
467.3
EPS(TTM)
Face Value()
Div & Yield %
22.04
10
0
 

ksb ltd
Stock Alert: IndusInd Bank, Indian Bank, Godrej Properties, Force Motors, Aurobindo Pharma
Apr 07,2025
Securities in F&O Ban:

Birlasoft and Hindustan Copper shares are banned from F&O Trading on 7 April 2025.

Stocks to Watch:

IndusInd Bank’s total deposits jumped 6.8% to Rs 4,11,140 crore as of 31st March 2025 as compared with Rs 3,84,793 crore as of 31st March 2024.

Force Motors’ domestic sales jumped 11.02% to 3,606 units in March 2025, as against 3,248 units sold in March 2024.

Indian Bank’s total deposits jumped 7.12% to Rs 7.37 lakh crore as of 31st March 2025 as compared with Rs 6.88 lakh crore as of 31st March 2024.

Godrej Properties has entered into an agreement for development of a prime land parcel in Versova, Mumbai. This project is estimated to have a developable potential of approximately 4.4 lakh square feet of saleable area, with an estimated revenue potential of nearly Rs 1,350 crore.

Bajel Projects' board of directors has appointed Nitesh Bhandari as chief financial officer (CFO) & joint president of the company, effective from 1 May 2025.

KSB has received letter of award for a solar water project worth Rs 14 crore from Tripura Renewable Energy Development Agency. It secured another letter of award for a solar water project worth Rs 49 crore from Maharashtra State Electricity Distribution.

Aurobindo Pharma’s wholly owned step-down subsidiary, CuraTeQ Biologics s.r.o, has received permission from European Commission (EC) to market Dyrupeg in European Union.